Heparin-Induced Thrombocytopenia

• DOI: 10.18087/cardio.2024.5.n2186
• Publication Date: 2024-06-06T07:57:41Z
• Authors: A. B. Sugraliyev
• Keywords: Heparin-Induced Thrombocytopenia

The extensive use of therapeutic doses heparin to prevent thrombosis in critically ill patients with COVID-19 during the pandemic has led an increased incidence bleeding and heparin-induced thrombocytopenia (HIT). In addition, introduction AstraZeneca Johnson&Johnson vaccines against into clinical practice was associated development a rare but very severe, adverse thrombotic complication, vaccine-induced immune (VITT). Thrombotic complications VITT turned out be similar HIT both clinically pathophysiologically. is potentially fatal immune-mediated drug response that results emergence antibodies activate platelets presence heparin. characterized by high venous arterial thromboses, often outcomes. Currently, there are clearly defined international guidelines for diagnosis, treatment prevention HIT. case complications, non-heparin anticoagulants should used.